Determination of the therapeutic effect of vulpinic acid as a drug candidate molecule in ovarian cancer

Ovarian cancers continue to be the most important cause of mortality among gynecological cancers in developed and developing countries. It is the fifth most common cancer among women, and is the fourth most common cancer death in women. Prostate, ovarian and breast cancers are heterogeneous and the patient is faced with therapeutic resistance problems that develop over time. Therefore, determining the effectiveness of molecules with alternative therapeutic properties is a hope for cancer patients. The antiproliferative effect of vulpinic acid on OVCAR-3 and SKOV-3 ovarian cancer cells and OSE ovarian normal epithelial cell will be evaluated using the Xcelligence device. The success of drug treatment in cancer patients who have metastasized is based on the ability of the cells to maintain their ability to undergo apoptosis. Therefore, cell cycle analysis and apoptotic effect of vulpinic acid on ovarian cancer cells will be determined by flow-cytometer. In addition, the expression level of the apoptotic effect of the 77 genes belonging to the apoptosis pathway in mRNA size will be determined by qRT-PCR and the protein size will be confirmed by western blot method. According to the results obtained, it will be possible to determine the effectiveness of the use of vulpinic acid as a promising candidate molecule in ovarian cancer. Moreover, the potential of a natural molecule of biological origin that does not cause any side effects in patients will be supported with clinical applications, and the use of medicines for the treatment of ovarian cancer will be provided.